Denali Therapeutics
DNLI
DNLI
204 hedge funds and large institutions have $6.13B invested in Denali Therapeutics in 2020 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 62 increasing their positions, 67 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
20% more funds holding
Funds holding: 170 → 204 (+34)
7% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 67
4.18% less ownership
Funds ownership: 78.09% → 73.91% (-4.2%)
Holders
204
Holding in Top 10
5
Calls
$29.3M
Puts
$5.76M
Top Buyers
| 1 | +$176M | |
| 2 | +$126M | |
| 3 | +$114M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$111M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$102M |
Top Sellers
| 1 | -$272M | |
| 2 | -$114M | |
| 3 | -$73.5M | |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$71.5M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$56.7M |